Insider filing · MDGL
Robert E. Waltermire
Senior VP, Chief Pharma Dev.
profile →
Madrigal Pharmaceuticals, Inc.
MDGL · Healthcare · 60 filings in 24 months
ticker →
Robert E. Waltermire sold $4.8M of Madrigal Pharmaceuticals (MDGL)
Executed Mar 5 2025, disclosed Mar 7 2025, 2 days later.
Value, as filed
$4.8M
14,113 sh across 9 lots
Executed
Mar 5 2025
the trade date, as filed
Disclosed
Mar 7 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
RWRobert E. Waltermire (Senior VP, Chief Pharma Dev.) filed 3 Form 4 reports in the past 24 months (0 purchases, 3 sales), most often in Madrigal Pharmaceuticals, Inc. (MDGL). The largest single filing was $4.8M of MDGL (14,113 sh across 9 lots, as filed), executed Mar 5 2025.
The name
MDGLHealthcare · Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Robert E. Waltermire in MDGL
MDGLSALE
Madrigal Pharmaceuticals, Inc.
$359K1,052 sh × $340.99
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. $121K
442 sh × $273.41
Exec Jan 17 2025
Filed Jan 17 2025 · 5:30 PM ET